Search

Your search keyword '"Alva, Ajjai S."' showing total 209 results
Start Over Author "Alva, Ajjai S."
209 results on '"Alva, Ajjai S."'

1. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

Author

Orme, Jacob J., Taza, Fadi, De Sarkar, Navonil, Tewari, Alok K., Arsalan Naqvi, Syed, Riaz, Irbaz B., Childs, Daniel S., Omar, Noha, Adra, Nabil, Ashkar, Ryan, Cheng, Heather H., Schweizer, Michael T., Sokolova, Alexandra O., Agarwal, Neeraj, Barata, Pedro, Sartor, Oliver, Bastos, Diogo, Smaletz, Oren, Berchuck, Jacob E., McClure, Heather, Taplin, Mary-Ellen, Aggarwal, Rahul, Sternberg, Cora N., Vlachostergios, Panagiotis J., Alva, Ajjai S., Mehra, Niven, Nelson, Peter S., Hwang, Justin, Dehm, Scott M., Shi, Qian, Fleischmann, Zoe, Sokol, Ethan S., Elliott, Andrew, Huang, Haojie, Bryce, Alan, Marshall, Catherine H., and Antonarakis, Emmanuel S.

Published
2024
Full Text
View/download PDF

2. Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

Author

Gong, Jun, Mita, Alain C., Wei, Zihan, Cheng, Heather H., Mitchell, Edith P., Wright, John J., Ivy, S. Percy, Wang, Victoria, Gray, Robert C., McShane, Lisa M., Rubinstein, Larry V., Patton, David R., Williams, P. Mickey, Hamilton, Stanley R., Alva, Ajjai S., Tricoli, James V., Conley, Barbara A., Arteaga, Carlos L., Harris, Lyndsay N., OʼDwyer, Peter J., Chen, Alice P., and Flaherty, Keith T.

Published
2024
Full Text
View/download PDF

3. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations

Author

Park, Joseph J., Chu, Alec, Li, Jinju, Ali, Alicia, McKay, Rana R., Hwang, Clara, Labriola, Matthew K., Jang, Albert, Kilari, Deepak, Mo, George, Ravindranathan, Deepak, Graham, Laura S., Sokolova, Alexandra, Tripathi, Abhishek, Pilling, Amanda, Jindal, Tanya, Ravindra, Aditya, Cackowski, Frank C., Sweeney, Patrick L., Thapa, Bicky, Amery, Taylor S., Heath, Elisabeth I., Garje, Rohan, Zakharia, Yousef, Koshkin, Vadim S., Bilen, Mehmet A., Schweizer, Michael T., Barata, Pedro C., Dorff, Tanya B., Cieslik, Marcin, Alva, Ajjai S., and Armstrong, Andrew J.

Published
2024
Full Text
View/download PDF

4. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).

Author

Pienta, Kenneth J, Gorin, Michael A, Rowe, Steven P, Carroll, Peter R, Pouliot, Frédéric, Probst, Stephan, Saperstein, Lawrence, Preston, Mark A, Alva, Ajjai S, Patnaik, Akash, Durack, Jeremy C, Stambler, Nancy, Lin, Tess, Jensen, Jessica, Wong, Vivien, Siegel, Barry A, and Morris, Michael J

Subjects
Humans, Prostatic Neoplasms, Neoplasm Metastasis, Urea, Prostate-Specific Antigen, Lysine, Prospective Studies, Reproducibility of Results, Aged, Aged, 80 and over, Middle Aged, Male, Positron Emission Tomography Computed Tomography, molecular imaging, neoplasm metastasis, neoplasm staging, prostatic neoplasms, Prevention, Cancer, Clinical Trials and Supportive Activities, Urologic Diseases, Clinical Research, Aging, Prostate Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Clinical Sciences, Urology & Nephrology
Abstract

PurposeProstate specific membrane antigen-targeted positron emission tomography/computerized tomography has the potential to improve the detection and localization of prostate cancer. OSPREY was a prospective trial designed to determine the diagnostic performance of 18F-DCFPyL-positron emission tomography/computerized tomography for detecting sites of metastatic prostate cancer.Materials and methodsTwo patient populations underwent 18F-DCFPyL-positron emission tomography/computerized tomography. Cohort A enrolled men with high-risk prostate cancer undergoing radical prostatectomy with pelvic lymphadenectomy. Cohort B enrolled patients with suspected recurrent/metastatic prostate cancer on conventional imaging. Three blinded central readers evaluated the 18F-DCFPyL-positron emission tomography/computerized tomography. Diagnostic performance of 18F-DCFPyL-positron emission tomography/computerized tomography was based on imaging results compared to histopathology. In cohort A, detection of pelvic nodal disease (with specificity and sensitivity as co-primary end points) and of extrapelvic metastases were evaluated. In cohort B, sensitivity and positive predictive value for prostate cancer within biopsied lesions were evaluated.ResultsA total of 385 patients were enrolled. In cohort A (252 evaluable patients), 18F-DCFPyL-positron emission tomography/computerized tomography had median specificity of 97.9% (95% CI: 94.5%-99.4%) and median sensitivity of 40.3% (28.1%-52.5%, not meeting prespecified end point) among 3 readers for pelvic nodal involvement; median positive predictive value and negative predictive value were 86.7% (69.7%-95.3%) and 83.2% (78.2%-88.1%), respectively. In cohort B (93 evaluable patients, median prostate specific antigen 11.3 ng/ml), median sensitivity and positive predictive value for extraprostatic lesions were 95.8% (87.8%-99.0%) and 81.9% (73.7%-90.2%), respectively.ConclusionsThe primary end point for specificity was met while the primary end point for sensitivity was not. The high positive predictive value observed in both cohorts indicates that 18F-DCFPyL-positive lesions are likely to represent disease, supporting the potential utility of 18F-DCFPyL-positron emission tomography/computerized tomography to stage men with high-risk prostate cancer for nodal or distant metastases, and reliably detect sites of disease in men with suspected metastatic prostate cancer.

Published
2021

5. Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Ahn, Eugene R., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Calfa, Carmen J., Alva, Ajjai S., Suhag, Vijay, Alese, Olatunji B., Dotan, Efrat, Hamid, Omid, Yang, Eddy S., Marr, Alissa S., Palmer, Martin C., Thompson, Forrest L., Yost, Kathleen J., Gregory, Abigail, Grantham, Gina N., Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.

Published
2024
Full Text
View/download PDF

6. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

Author

Ryan, Christopher W, Tangen, Catherine M, Heath, Elisabeth I, Stein, Mark N, Meng, Maxwell V, Alva, Ajjai S, Pal, Sumanta K, Puzanov, Igor, Clark, Joseph I, Choueiri, Toni K, Agarwal, Neeraj, Uzzo, Robert G, Haas, Naomi B, Synold, Timothy W, Plets, Melissa, Vaishampayan, Ulka N, Shuch, Brian M, Thompson, Ian M, Jr, and Lara, Primo N, Jr

Published
2023
Full Text
View/download PDF

8. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer

Author

Reimers, Melissa A, Yip, Steven M, Zhang, Li, Cieslik, Marcin, Dhawan, Mallika, Montgomery, Bruce, Wyatt, Alexander W, Chi, Kim N, Small, Eric J, Chinnaiyan, Arul M, Alva, Ajjai S, Feng, Felix Y, and Chou, Jonathan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prostate Cancer, Urologic Diseases, Clinical Research, Genetics, Cancer, Detection, screening and diagnosis, 2.1 Biological and endogenous factors, 4.1 Discovery and preclinical testing of markers and technologies, Aetiology, Aged, Cyclin-Dependent Kinases, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Prostatic Neoplasms, Retrospective Studies, Treatment Outcome, Genomics, Next-generation sequencing, Prostate cancer, Cyclin-dependent kinase 12, Urology & Nephrology, Clinical sciences
Abstract

BackgroundCyclin-dependent kinase 12 (CDK12) loss occurs in 3-7% of metastatic prostate cancer patients and is characterized by a genomic instability signature, but the clinical implications of CDK12 loss are not well established.ObjectiveTo determine the clinical course of patients with CDK12 mutant advanced prostate cancer compared with other genomic subtypes.Design, setting, and participantsA retrospective analysis of data from three academic medical centers, including 317 patients with advanced prostate cancer and prior next-generation sequencing from tumor tissue (n = 172) or circulating tumor DNA (n = 145), was performed. Forty-six patients had CDK12 mutations; 34 had biallelic CDK12 loss (79%).Outcome measurements and statistical analysisPatients were stratified by mutation status (CDK12, homologous recombination deficiency [HRD; BRCA1/2 and ATM], TP53, and other cohort). The Kaplan-Meier method was used to evaluate time to event outcomes: time to development of metastatic disease, time to development of castration resistance, and time to prostate-specific antigen (PSA) progression after first-line androgen receptor pathway inhibitor (ARPI) therapy in a patient subset.Results and limitationsThe median follow-up was 66.6 mo. Patients with CDK12 mutant prostate cancer exhibited shorter time to metastasis (median = 34.9 mo, p =  0.004) and development of castration-resistant disease (median = 32.7 mo, p

Published
2020

9. Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

Author

Nguyen, Charles B., primary, Reimers, Melissa A., additional, Perera, Chamila, additional, Abida, Wassim, additional, Chou, Jonathan, additional, Feng, Felix Y., additional, Antonarakis, Emmanuel S., additional, McKay, Rana R., additional, Pachynski, Russell K., additional, Zhang, Jingsong, additional, Reichert, Zachery R., additional, Palmbos, Phillip L., additional, Caram, Megan E.V., additional, Vaishampayan, Ulka N., additional, Heath, Elisabeth I., additional, Hopkins, Alexander C., additional, Cieslik, Marcin P., additional, Wu, Yi-Mi, additional, Robinson, Dan, additional, Baladandayuthapani, Veerabhadran, additional, Chinnaiyan, Arul M., additional, and Alva, Ajjai S., additional

Published
2024
Full Text
View/download PDF

10. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy

Author

Hovelson, Daniel H, Liu, Chia-Jen, Wang, Yugang, Kang, Qing, Henderson, James, Gursky, Amy, Brockman, Scott, Ramnath, Nithya, Krauss, John C, Talpaz, Moshe, Kandarpa, Malathi, Chugh, Rashmi, Tuck, Missy, Herman, Kirk, Grasso, Catherine S, Quist, Michael J, Feng, Felix Y, Haakenson, Christine, Langmore, John, Kamberov, Emmanuel, Tesmer, Tim, Husain, Hatim, Lonigro, Robert J, Robinson, Dan, Smith, David C, Alva, Ajjai S, Hussain, Maha H, Chinnaiyan, Arul M, Tewari, Muneesh, Mills, Ryan E, Morgan, Todd M, and Tomlins, Scott A

Subjects
Human Genome, Cancer, Prostate Cancer, Biotechnology, Genetics, Good Health and Well Being, cell-free DNA, precision oncology, prostate cancer, whole genome sequencing, copy-number analysis, Oncology and Carcinogenesis
Abstract

Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We sought to demonstrate the utility of a pan-cancer, rapid, inexpensive, whole genome NGS of cfDNA approach (PRINCe) as a precision oncology screening strategy via ultra-low coverage (~0.01x) tumor content determination through genome-wide copy number alteration (CNA) profiling. We applied PRINCe to a retrospective cohort of 124 cfDNA samples from 100 patients with advanced cancers, including 76 men with metastatic castration-resistant prostate cancer (mCRPC), enabling cfDNA tumor content approximation and actionable focal CNA detection, while facilitating concordance analyses between cfDNA and tissue-based NGS profiles and assessment of cfDNA alteration associations with mCRPC treatment outcomes. Therapeutically relevant focal CNAs were present in 42 (34%) cfDNA samples, including 36 of 93 (39%) mCRPC patient samples harboring AR amplification. PRINCe identified pre-treatment cfDNA CNA profiles facilitating disease monitoring. Combining PRINCe with routine targeted NGS of cfDNA enabled mutation and CNA assessment with coverages tuned to cfDNA tumor content. In mCRPC, genome-wide PRINCe cfDNA and matched tissue CNA profiles showed high concordance (median Pearson correlation = 0.87), and PRINCe detectable AR amplifications predicted reduced time on therapy, independent of therapy type (Kaplan-Meier log-rank test, chi-square = 24.9, p < 0.0001). Our screening approach enables robust, broadly applicable cfDNA-based precision oncology for patients with advanced cancer through scalable identification of therapeutically relevant CNAs and pre-/post-treatment genomic profiles, enabling cfDNA- or tissue-based precision oncology workflow optimization.

Published
2017

11. Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers

Author

Martinez Chanza, Nieves, Werner, Lillian, Plimack, Elizabeth, Yu, Evan Y., Alva, Ajjai S., Crabb, Simon J., Powles, Thomas, Rosenberg, Jonathan E., Baniel, Jack, Vaishampayan, Ulka N., Berthold, Dominik R., Ladoire, Sylvain, Hussain, Syed A., Milowsky, Matthew I., Agarwal, Neeraj, Necchi, Andrea, Pal, Sumanta K., Sternberg, Cora N., Bellmunt, Joaquim, Galsky, Matthew D., and Harshman, Lauren C.

Published
2020
Full Text
View/download PDF

14. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

Author

Orme, Jacob J., primary, Taza, Fadi, additional, De Sarkar, Navonil, additional, Tewari, Alok K., additional, Arsalan Naqvi, Syed, additional, Riaz, Irbaz B., additional, Childs, Daniel S., additional, Omar, Noha, additional, Adra, Nabil, additional, Ashkar, Ryan, additional, Cheng, Heather H., additional, Schweizer, Michael T., additional, Sokolova, Alexandra O., additional, Agarwal, Neeraj, additional, Barata, Pedro, additional, Sartor, Oliver, additional, Bastos, Diogo, additional, Smaletz, Oren, additional, Berchuck, Jacob E., additional, McClure, Heather, additional, Taplin, Mary-Ellen, additional, Aggarwal, Rahul, additional, Sternberg, Cora N., additional, Vlachostergios, Panagiotis J., additional, Alva, Ajjai S., additional, Mehra, Niven, additional, Nelson, Peter S., additional, Hwang, Justin, additional, Dehm, Scott M., additional, Shi, Qian, additional, Fleischmann, Zoe, additional, Sokol, Ethan S., additional, Elliott, Andrew, additional, Huang, Haojie, additional, Bryce, Alan, additional, Marshall, Catherine H., additional, and Antonarakis, Emmanuel S., additional

Published
2023
Full Text
View/download PDF

15. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer

Author

Hwang, Clara, primary, Henderson, Nicholas C., additional, Chu, Shih-Chun, additional, Holland, Brandon, additional, Cackowski, Frank C., additional, Pilling, Amanda, additional, Jang, Albert, additional, Rothstein, Shoshana, additional, Labriola, Matthew, additional, Park, Joseph J., additional, Ghose, Alyssa, additional, Bilen, Mehmet A., additional, Mustafa, Seema, additional, Kilari, Deepak, additional, Pierro, Michael J., additional, Thapa, Bicky, additional, Tripathi, Abhishek, additional, Garje, Rohan, additional, Ravindra, Aditya, additional, Koshkin, Vadim S., additional, Hernandez, Erik, additional, Schweizer, Michael T., additional, Armstrong, Andrew J., additional, McKay, Rana R., additional, Dorff, Tanya B., additional, Alva, Ajjai S., additional, and Barata, Pedro C., additional

Published
2023
Full Text
View/download PDF

16. De novo neuroendocrine transdifferentiation in primary prostate cancer–a phenotype associated with advanced clinico-pathologic features and aggressive outcome

Author

Abdulfatah, Eman, Reichert, Zachery R., Davenport, Matthew S., Chinnaiyan, Arul M., Dadhania, Vipulkumar, Wang, Xiaoming, Mannan, Rahul, Kunju, Lakshmi P., Hollenbeck, Brent K., Montgomery, Jeffrey S., Kaffenberger, Samuel D., Morgan, Todd M., Alva, Ajjai S., Palapattu, Ganesh S., Vaishampayan, Ulka N., Alumkal, Joshi J., Spratt, Daniel E., Udager, Aaron M., and Mehra, Rohit

Published
2021
Full Text
View/download PDF

19. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer

Author

Taza, Fadi, Holler, Albert E., Fu, Wei, Wang, Hao, Adra, Nabil, Albany, Costantine, Ashkar, Ryan, Cheng, Heather H., Sokolova, Alexandra O., Agarwal, Neeraj, Kessel, Adam, Bryce, Alan, Nafissi, Nellie, Barata, Pedro, Sartor, A. Oliver, Bastos, Diogo, Smaletz, Oren, Berchuck, Jacob E., Taplin, Mary-Ellen, Aggarwal, Rahul, Sternberg, Cora N., Vlachostergios, Panagiotis J., Alva, Ajjai S., Su, Christopher, Marshall, Catherine H., and Antonarakis, Emmanuel S.

Published
2021
Full Text
View/download PDF

20. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Duvivier, Herbert L., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ahn, Eugene R., additional, Al Baghdadi, Tareq, additional, Alva, Ajjai S., additional, Dublis, Stephanie A., additional, Cannon, Timothy L., additional, Calfa, Carmen J., additional, Li, Rui, additional, Behl, Deepti, additional, Chiu, Vi K., additional, Gold, Philip J., additional, Marr, Alissa S., additional, Mileham, Kathryn F., additional, Powell, Steven Francis, additional, Rodon, Jordi, additional, Thota, Ramya, additional, Grantham, Gina N., additional, Gregory, Abigail, additional, Hinshaw, Dominique C., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

24. Abstract 2244: Association of chromosomal instability with poor prognosis in metastatic hormone sensitive and castrate-resistant prostate cancer

Author

Rebernick, Ryan J., primary, Hammer, Liat, additional, McFarlane, Matthew, additional, Westbrook, Thomas, additional, Hazime, Munna, additional, Hammoud, Tanya, additional, Chiu, Pin-en, additional, Wu, Yi-Mi, additional, Robinson, Dan, additional, Spratt, Daniel Eidelberg, additional, Alva, Ajjai S., additional, Jackson, William C., additional, Reichert, Zachery R., additional, Chinnaiyan, Arul, additional, Alumkal, Joshi J., additional, Dess, Robert T., additional, and Cieslik, Marcin, additional

Published
2023
Full Text
View/download PDF

25. Data from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer

Author

Xiao, Lanbo, primary, Tien, Jean C., primary, Vo, Josh, primary, Tan, Mengyao, primary, Parolia, Abhijit, primary, Zhang, Yajia, primary, Wang, Lisha, primary, Qiao, Yuanyuan, primary, Shukla, Sudhanshu, primary, Wang, Xiaoju, primary, Zheng, Heng, primary, Su, Fengyun, primary, Jing, Xiaojun, primary, Luo, Esther, primary, Delekta, Andrew, primary, Juckette, Kristin M., primary, Xu, Alice, primary, Cao, Xuhong, primary, Alva, Ajjai S., primary, Kim, Youngsoo, primary, MacLeod, A. Robert, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer

Author

Xiao, Lanbo, primary, Tien, Jean C., primary, Vo, Josh, primary, Tan, Mengyao, primary, Parolia, Abhijit, primary, Zhang, Yajia, primary, Wang, Lisha, primary, Qiao, Yuanyuan, primary, Shukla, Sudhanshu, primary, Wang, Xiaoju, primary, Zheng, Heng, primary, Su, Fengyun, primary, Jing, Xiaojun, primary, Luo, Esther, primary, Delekta, Andrew, primary, Juckette, Kristin M., primary, Xu, Alice, primary, Cao, Xuhong, primary, Alva, Ajjai S., primary, Kim, Youngsoo, primary, MacLeod, A. Robert, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Methods and References from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

Author

McDaniel, Andrew S., primary, Hovelson, Daniel H., primary, Cani, Andi K., primary, Liu, Chia-Jen, primary, Zhai, Yali, primary, Zhang, Yajia, primary, Weizer, Alon Z., primary, Mehra, Rohit, primary, Feng, Felix Y., primary, Alva, Ajjai S., primary, Morgan, Todd M., primary, Montgomery, Jeffrey S., primary, Siddiqui, Javed, primary, Sadis, Seth, primary, Bandla, Santhoshi, primary, Williams, Paul D., primary, Cho, Kathleen R., primary, Rhodes, Daniel R., primary, and Tomlins, Scott A., primary

Published
2023
Full Text
View/download PDF

28. Data from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

Author

McDaniel, Andrew S., primary, Hovelson, Daniel H., primary, Cani, Andi K., primary, Liu, Chia-Jen, primary, Zhai, Yali, primary, Zhang, Yajia, primary, Weizer, Alon Z., primary, Mehra, Rohit, primary, Feng, Felix Y., primary, Alva, Ajjai S., primary, Morgan, Todd M., primary, Montgomery, Jeffrey S., primary, Siddiqui, Javed, primary, Sadis, Seth, primary, Bandla, Santhoshi, primary, Williams, Paul D., primary, Cho, Kathleen R., primary, Rhodes, Daniel R., primary, and Tomlins, Scott A., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figures S1-S5 from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

Author

McDaniel, Andrew S., primary, Hovelson, Daniel H., primary, Cani, Andi K., primary, Liu, Chia-Jen, primary, Zhai, Yali, primary, Zhang, Yajia, primary, Weizer, Alon Z., primary, Mehra, Rohit, primary, Feng, Felix Y., primary, Alva, Ajjai S., primary, Morgan, Todd M., primary, Montgomery, Jeffrey S., primary, Siddiqui, Javed, primary, Sadis, Seth, primary, Bandla, Santhoshi, primary, Williams, Paul D., primary, Cho, Kathleen R., primary, Rhodes, Daniel R., primary, and Tomlins, Scott A., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure Legends from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

Author

McDaniel, Andrew S., primary, Hovelson, Daniel H., primary, Cani, Andi K., primary, Liu, Chia-Jen, primary, Zhai, Yali, primary, Zhang, Yajia, primary, Weizer, Alon Z., primary, Mehra, Rohit, primary, Feng, Felix Y., primary, Alva, Ajjai S., primary, Morgan, Todd M., primary, Montgomery, Jeffrey S., primary, Siddiqui, Javed, primary, Sadis, Seth, primary, Bandla, Santhoshi, primary, Williams, Paul D., primary, Cho, Kathleen R., primary, Rhodes, Daniel R., primary, and Tomlins, Scott A., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Tables S1-S4 from Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

Author

McDaniel, Andrew S., primary, Hovelson, Daniel H., primary, Cani, Andi K., primary, Liu, Chia-Jen, primary, Zhai, Yali, primary, Zhang, Yajia, primary, Weizer, Alon Z., primary, Mehra, Rohit, primary, Feng, Felix Y., primary, Alva, Ajjai S., primary, Morgan, Todd M., primary, Montgomery, Jeffrey S., primary, Siddiqui, Javed, primary, Sadis, Seth, primary, Bandla, Santhoshi, primary, Williams, Paul D., primary, Cho, Kathleen R., primary, Rhodes, Daniel R., primary, and Tomlins, Scott A., primary

Published
2023
Full Text
View/download PDF

33. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

Author

Takemura, Kosuke, primary, Navani, Vishal, additional, Ernst, Matthew S., additional, Wells, J. Connor, additional, Meza, Luis, additional, Pal, Sumanta K., additional, Lee, Jae-Lyun, additional, Li, Haoran, additional, Agarwal, Neeraj, additional, Alva, Ajjai S., additional, Hansen, Aaron R., additional, Basappa, Naveen S., additional, Szabados, Bernadett, additional, Powles, Thomas, additional, Tran, Ben, additional, Hocking, Christopher M., additional, Beuselinck, Benoit, additional, Yuasa, Takeshi, additional, Choueiri, Toni K., additional, and Heng, Daniel Y. C., additional

Published
2022
Full Text
View/download PDF

34. Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2 ‐mutated metastatic castrate‐resistant prostate cancer

Author

Su, Christopher T., primary, Nizialek, Emily, additional, Berchuck, Jacob E., additional, Vlachostergios, Panagiotis J., additional, Ashkar, Ryan, additional, Sokolova, Alexandra, additional, Barata, Pedro C., additional, Aggarwal, Rahul R., additional, McKay, Rana R., additional, Agarwal, Neeraj, additional, McClure, Heather M., additional, Nafissi, Nellie, additional, Bryce, Alan H., additional, Sartor, Oliver, additional, Sayegh, Nicolas, additional, Cheng, Heather H., additional, Adra, Nabil, additional, Sternberg, Cora N., additional, Taplin, Mary‐Ellen, additional, Cieslik, Marcin, additional, Alva, Ajjai S., additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

37. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.

Author

Kosuke Takemura, Navani, Vishal, Ernst, Matthew S., Wells, J. Connor, Meza, Luis, Pal, Sumanta K., Jae-Lyun Lee, Li, Haoran, Agarwal, Neeraj, Alva, Ajjai S., Hansen, Aaron R., Basappa, Naveen S., Szabados, Bernadett, Powles, Thomas, Tran, Ben, Hocking, Christopher M., Beuselinck, Benoit, Takeshi Yuasa, Choueiri, Toni K., and Heng, Daniel Y. C.

Subjects
RENAL cell carcinoma, PROTEIN-tyrosine kinase inhibitors, DATABASES, VASCULAR endothelial growth factors
Abstract

Purpose: Clinical trials have demonstrated higher complete response rates in the immuno-oncologye based combination arms than in the tyrosine kinase inhibitor arms in patients with metastatic renal cell carcinoma. We aimed to characterize real-world patients who experienced complete response to the contemporary first-line therapies. Materials and Methods: Using the International Metastatic Renal Cell Carcinoma Database Consortium, response-evaluable patients who received frontline immuno-oncologye based combination therapy or tyrosine kinase inhibitor monotherapy were analyzed. Baseline characteristics of patients and post-landmark overall survival were compared based on best overall response, as per RECIST 1.1. Results: A total of 52 (4.6%) of 1,126 and 223 (3.0%) of 7,557 patients experienced complete response to immuno-oncologye based and tyrosine kinase inhibitor therapies, respectively (P [ .005). An adjusted odds ratio for complete response achieved by immuno-oncologye based combination therapy (vs tyrosine kinase inhibitor monotherapy) was 1.56 (95% CI 1.11-2.17; P [ .009). Among patients who experienced complete response, the immuno-oncologye based cohort had a higher proportion of noneclear cell histology (15.9% and 4.7%; P [ .016), sarcomatoid dedifferentiation (29.8% and 13.5%; P [ .014), and multiple sites of metastases (80.4% and 50.0%; P < .001) than the tyrosine kinase inhibitor cohort. Complete response was independently associated with post-landmark overall survival benefit in both the immuno-oncologye based and tyrosine kinase inhibitor cohorts, giving respective adjusted hazard ratios of 0.17 (95% CI 0.04-0.72; P [ .016) and 0.28 (95% CI 0.21-0.38; P < .001). Conclusions: The complete response rate was not as high in the real-world population as in the clinical trial population. Among those who experienced complete response, several adverse clinicopathological features were more frequently observed in the immuno-oncologye based cohort than in the tyrosine kinase inhibitor cohort. Complete response was an indicator of favorable overall survival. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Author

Koshkin, Vadim S., primary, Henderson, Nicholas, additional, James, Marihella, additional, Natesan, Divya, additional, Freeman, Dory, additional, Nizam, Amanda, additional, Su, Christopher T., additional, Khaki, Ali Raza, additional, Osterman, Chelsea K., additional, Glover, Michael J., additional, Chiang, Ryan, additional, Makrakis, Dimitrios, additional, Talukder, Rafee, additional, Lemke, Emily, additional, Olsen, T. Anders, additional, Jain, Jayanshu, additional, Jang, Albert, additional, Ali, Alicia, additional, Jindal, Tanya, additional, Chou, Jonathan, additional, Friedlander, Terence W., additional, Hoimes, Christopher, additional, Basu, Arnab, additional, Zakharia, Yousef, additional, Barata, Pedro C., additional, Bilen, Mehmet A., additional, Emamekhoo, Hamid, additional, Davis, Nancy B., additional, Shah, Sumit A., additional, Milowsky, Matthew I., additional, Gupta, Shilpa, additional, Campbell, Matthew T., additional, Grivas, Petros, additional, Sonpavde, Guru P., additional, Kilari, Deepak, additional, and Alva, Ajjai S., additional

Published
2021
Full Text
View/download PDF

39. MP11-11 CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL

Author

Carroll, Peter R., primary, Probst, Stephan, additional, Rowe, Steven P., additional, Gorin, Michael A., additional, Pienta, Kenneth J., additional, Saperstein, Lawrence, additional, Pouliot, Frédéric, additional, Patnaik, Akash, additional, Preston, Mark A., additional, Alva, Ajjai S., additional, Stambler, Nancy, additional, Siegel, Barry A., additional, and Morris, Michael J., additional

Published
2021
Full Text
View/download PDF

40. Case report: Immunemediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma.

Author

Nguyen, Charles B., Su, Christopher T., Morgan, Meredith, and Alva, Ajjai S.

Subjects
MEIBOMIAN glands, DRUG side effects, TRANSITIONAL cell carcinoma, IMMUNE checkpoint inhibitors, OCULAR toxicology, MYASTHENIA gravis
Abstract

Ocular immune-related adverse events are a relatively rare complication of immune checkpoint inhibitors. Common ocular toxicities range from dry eyes to inflammatory uveitis and ocular myasthenia gravis. Here, we present the case of a 55-year-old woman with recurrent urothelial carcinoma of the ureter after initially being managed with neoadjuvant cisplatin-based chemotherapy and surgical resection. She was treated with pembrolizumab which was complicated by immune-mediated pneumonitis after the eighth cycle, which was managed with a prolonged steroid course. The patient also developed red eyes along with recurrent styes. Eye examination revealed decreased tear breakup time, expression of thick and turbid meibum, and meibomian gland atrophy on infrared meibography. The patient was diagnosed with suspected immune-mediated meibomian gland dysfunction (MGD) as a result of pembrolizumab, a previously unreported complication of immunotherapy. The goal of MGD therapy is to stabilize the tear film and minimize evaporation with lipid-based lubricants and other conservative treatments. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Alva, Ajjai S., primary, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Hansra, Damien, additional, Calfa, Carmen J., additional, Khalil, Maged F., additional, Ahn, Eugene R., additional, Cannon, Timothy L., additional, Crilley, Pamela, additional, Fisher, Julie G., additional, Haslem, Derrick S., additional, Shrestha, Sagun, additional, Antonelli, Kaitlyn R., additional, Butler, Nicole L., additional, Warren, Sasha L., additional, Rygiel, Andrew L., additional, Ranasinghe, Shamika, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2021
Full Text
View/download PDF

42. Reply by Authors

Author

Pienta, Kenneth J., primary, Gorin, Michael A., additional, Rowe, Steven P., additional, Carroll, Peter R., additional, Pouliot, Frédéric, additional, Probst, Stephan, additional, Saperstein, Lawrence, additional, Preston, Mark A., additional, Alva, Ajjai S., additional, Patnaik, Akash, additional, Durack, Jeremy C., additional, Stambler, Nancy, additional, Lin, Tess, additional, Jensen, Jessica, additional, Wong, Vivien, additional, Siegel, Barry A., additional, and Morris, Michael J., additional

Published
2021
Full Text
View/download PDF

43. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors

Author

Ma, Vincent T., primary, Su, Christopher T., additional, Hu, Miriam, additional, Taylor, Jeremy M.G., additional, Daignault-Newton, Stephanie, additional, Kellezi, Olesia, additional, Dahl, Megan N., additional, Shah, Miloni A., additional, Erickson, Stephanie, additional, Lora, Jessica, additional, Hamasha, Reema, additional, Ali, Alicia, additional, Yancey, Sabrina, additional, Kiros, Leah, additional, Balicki, Hannah M., additional, Winfield, Daniel C., additional, Green, Michael D., additional, and Alva, Ajjai S., additional

Published
2021
Full Text
View/download PDF

44. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY)

Author

Pienta, Kenneth J., primary, Gorin, Michael A., additional, Rowe, Steven P., additional, Carroll, Peter R., additional, Pouliot, Frédéric, additional, Probst, Stephan, additional, Saperstein, Lawrence, additional, Preston, Mark A., additional, Alva, Ajjai S., additional, Patnaik, Akash, additional, Durack, Jeremy C., additional, Stambler, Nancy, additional, Lin, Tess, additional, Jensen, Jessica, additional, Wong, Vivien, additional, Siegel, Barry A., additional, and Morris, Michael J., additional

Published
2021
Full Text
View/download PDF

45. Differential treatment outcomes in BRCA1/2 ‐, CDK12 ‐, and ATM ‐mutated metastatic castration‐resistant prostate cancer

Author

Kwon, Daniel H., primary, Chou, Jonathan, additional, Yip, Steven M., additional, Reimers, Melissa A., additional, Zhang, Li, additional, Wright, Francis, additional, Dhawan, Mallika S., additional, Borno, Hala T., additional, Desai, Arpita, additional, Aggarwal, Rahul R., additional, Wyatt, Alexander W., additional, Small, Eric J., additional, Alva, Ajjai S., additional, Chi, Kim N., additional, Feng, Felix Y., additional, and Koshkin, Vadim S., additional

Published
2021
Full Text
View/download PDF

46. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care

Author

Pennell, Nathan A., primary, Dillmon, Melissa, additional, Levit, Laura A., additional, Moushey, E. Allyn, additional, Alva, Ajjai S., additional, Blau, Sibel, additional, Cannon, Timothy L., additional, Dickson, Natalie R., additional, Diehn, Maximilian, additional, Gonen, Mithat, additional, Gonzalez, Maria Magdalena, additional, Hensold, Jack O., additional, Hinyard, Leslie J., additional, King, Tari, additional, Lindsey, Stacie C., additional, Magnuson, Allison, additional, Marron, Jonathan, additional, McAneny, Barbara L., additional, McDonnell, Theresa M., additional, Mileham, Kathryn Finch, additional, Nasso, Shelley Fuld, additional, Nowakowski, Grzegorz S., additional, Oettel, Kurt R., additional, Patel, Manali I., additional, Patt, Debra A., additional, Perlmutter, Jane, additional, Pickard, Todd A., additional, Rodriguez, Gladys, additional, Rosenberg, Abby R., additional, Russo, Barry, additional, Szczepanek, Connie, additional, Smith, Cardinale B., additional, Srivastava, Piyush, additional, Teplinsky, Eleonora, additional, Thota, Ramya, additional, Traina, Tiffany A., additional, Zon, Robin, additional, Bourbeau, Brian, additional, Bruinooge, Suanna S., additional, Foster, Shelagh, additional, Grubbs, Stephen, additional, Hagerty, Karen, additional, Hurley, Patricia, additional, Kamin, Deborah, additional, Phillips, Jonathan, additional, Schenkel, Caroline, additional, Schilsky, Richard L., additional, and Burris, Howard A., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results